PSD of cells at different densities. by Mingkun Pang (11873753)

Size-exclusion HPLC and SDS-PAGE Analysis of βA3ΔG91 vs WT mouse lens proteins. by Akosua K. Boateng (21672931)

Modified forms of the analytical solution (Eq (14)) of TSC motif. by Alok Kumar Maity (2212204)

Modified forms of the analytical solution (Eq (17)) of OCFFL motif. by Alok Kumar Maity (2212204)

Modified form of the analytical solution (Eq (23)) of ICFFL motif. by Alok Kumar Maity (2212204)

Modified forms of the analytical solution (Eq 18) of ACFFL motif. by Alok Kumar Maity (2212204)

<b>Anti-inflammation</b><b> </b><b>of </b><b>Rhapontici Radix</b><b> </b><b>mediated by </b><b>TMEM59 in MAC-T cells and mouse mammary gland</b> by Caode Jiang (11273817)

Modified form of the analytical expression given by Eq (11) for OSC motif. by Alok Kumar Maity (2212204)

Schematic presentation of different GTRN motifs. by Alok Kumar Maity (2212204)

Comparison of RMSE scores for the imputation of 269 highly differentially expressed genes of the A549 cell line. by Tong Si (1600378)

Results of the probabilistic sensitivity analysis. by Lara J. Wolfson (7224623)

Simultaneous HuD knockdown and overexpression of Msi2 reduces apoptosis in N2a cells. by Naina Gaikwad (20435889)

The OSC. by Alok Kumar Maity (2212204)

The ACFFL. by Alok Kumar Maity (2212204)

The TSC. by Alok Kumar Maity (2212204)

The OCFFL. by Alok Kumar Maity (2212204)

The ICFFL. by Alok Kumar Maity (2212204)

CXCL8 and CCL20 Enhance Osteoclastogenesis via Modulation of Cytokine Production by Human Primary Osteoblasts by Janak L. Pathak (759122)

Modeling of <i>In-Utero</i> and <i>Intra-Partum</i> Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV by Patumrat Sripan (741310)

“…We modeled <i>in-utero</i> and <i>intra-partum</i> HIV transmissions to investigate the preventive role of various antiretroviral treatments interventions.…”

Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials by Tao Cheng (1235148)

“…The onabotulinumtoxinA-treated groups had a significantly decreased mean number of urinary incontinence episodes per week (at week 6) (onabotulinumtoxinA200U: MD: -10.72, 95% CI: -13.4 to -8.04, P<0.00001; 300 U: MD: -11.42, 95% CI: -13.91 to -8.93, P<0.00001), MDP (200 U: MD: -33.46, 95% CI: -39.74 to -27.18, P<0.00001; 300 U: MD: -31.72, 95% CI: -37.69 to -25.75, P<0.00001), and greater increased MCC (200 U: MD: 141.30, 95% CI: 121.28 to 161.32, P<0.00001; 300 U: MD: 151.39, 95% CI: 130.43 to 172.34, P<0.00001) compared to the placebo-treated groups. …”